Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center
Articles
Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL
A panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.
Read More
Practice Patterns and Real Use of Epcoritamab and Glofitamab
A panel of experts discuss the role of odronextamab.
Read More
Bispecific therapy – management of long-term adverse events in the community setting
Read More
Bispecific therapy – treatment setting and management of short-term adverse events
Read More
Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line
Read More
Management of CRS and ICANS with CAR T-cell Therapy
A panel of experts discuss the incidence, severity, and management of AEs associated with CAR Tcell therapy.
Read More
Risk of Secondary Malignancies in Heavily Pre-Treated Population
A panel of experts discuss risk of secondary malignancies in heavily pre-treated populations.
Read More
Current Approach to Bridging Therapy in R/R DLBCL
A panel of experts discusses their individual approaches to bridging therapy in R/R DLBCL for patients eligible for CART
Read More
Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion
A panel of experts discuss current challenges for use of CAR T in R/R DLBCL.
Read More
Panel Discuses Use of CD19 Bispecifics in Sequencing
Bradley Hunter, MD, and Fred Locke, MD, and Elizabeth Budde, MD, PhD, share insights surrounding treatment considerations for CD19 targeting.
Read More
Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study
Dr Hunter discusses the decision making process around second-line therapies for transplant-ineligible patients, and further key clinical study data.
Read More
Multiple studies analyzing considerations for transplant-ineligible patients receiving second-line treatment with CAR T-cell therapy are discussed by key opinion leaders.
Read More
Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies
An examination of results from key studies in the DLBCL landscape are conducted by Dr Fred Locke.
Read More
Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices
Medical experts from various prestigious oncology institutions drive a conversation around referral patterns in the DLBCL treatment landscape.
Read More
Medical experts highlight second-line options for treating patients with DLBCL.
Read More
